Pathogenic Role of Abeta, tau and Inflammation in Inclusion Body Myositis

Abeta、tau 和炎症在包涵体肌炎中的致病作用

基本信息

  • 批准号:
    7486221
  • 负责人:
  • 金额:
    $ 8.36万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2007
  • 资助国家:
    美国
  • 起止时间:
    2007-08-17 至 2012-03-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Inclusion body myositis (IBM) is the leading age-related skeletal muscle disorder, yet its etiology remains unknown, nor do effective treatments exist. We developed novel transgenic models that mimic IBM-like motor deficits and pathology, including Aft accumulation and tau phosphorylation in skeletal muscle. This proposal investigates the genetic and pharmacologic factors that modulate the severity of IBM-like pathology in transgenic mice. Our preliminary data indicate that the accumulation of Aft plays a pivotal role in its pathogenesis. Consequently, factors that augment Aft, such as inflammation, exacerbate the phenotype, whereas we propose that interventions that reduce Afi may be an effective therapeutic strategy to delay or cure IBM. The first two aims are continuation of current studies. Aim 1 determines the pathologic effect of inflammatory responses in skeletal muscle on Aft and tau and also evaluate any anti-inflammatory agents modulate these IBM-like pathology. In aim 2,1 will utilize our transgenic IBM models to determine if Aft immunotherapy ameliorates the motor deficits and myopathology. We will investigate the effect of active immunization as a potential treatment for IBM; the outcome of this study may justify the initiation of a human clinical trial with IBM patients. The last aim (aim 3) focuses on the molecular link between myopathy and dementia, based on the current finding of genetic link between these diseases. I will generate novel transgenic mice harboring a clinical mutation in the valosin-containing protein (VCP) gene, responsible for IBM/Paget disease/frontotemporal dementia. Mutations on VCP may be involved in the abnormal accumulation of disease-relevant proteins found in both IBM and some neurodegenerative disorders. Thus, the mouse models will be useful both for therapeutic evaluation and for investigating any shared molecular mechanisms underlying the pathogenesis of these distinct diseases. This latter point is worth emphasizing as many dementia-related proteins accumulate in damaged muscle fibers in IBM, suggesting that there may be a coordinated cellular response to these proteins; thus, information learned from these models may be applicable to dementias like Alzheimer disease. Furthermore, providing multiple lines of disease models may accelerate the research progress in the field. Through this application, we hope to advance the understanding of IBM as well as dementias and evaluate potential therapeutic strategies for IBM.
描述(由申请人提供):包容体肌炎(IBM)是领先的与年龄有关的骨骼肌障碍,但其病因尚不清楚,也不存在有效的治疗方法。我们开发了模仿IBM样运动缺陷和病理学的新型转基因模型,包括骨骼肌中的AFT积累和TAU磷酸化。该建议研究了调节转基因小鼠IBM样病理严重程度的遗传和药理因素。我们的初步数据表明,船尾的积累在其发病机理中起关键作用。因此,增加船尾的因素(例如炎症)加剧了表型,而我们建议减少AFI的干预措施可能是延迟或治愈IBM的有效治疗策略。前两个目的是延续当前研究。 AIM 1确定骨骼肌对船尾和tau的病理作用,还评估任何抗炎剂调节这些IBM样病理学。在AIM 2,1中,将利用我们的转基因IBM模型来确定AFT免疫疗法是否可以缓解运动缺陷和肌病学。我们将研究主动免疫作为IBM的潜在治疗的影响;这项研究的结果可以证明与IBM患者的人类临床试验的启动合理。最后一个目标(目标3)重点是基于这些疾病之间遗传联系的目前发现,肌病和痴呆之间的分子联系。我将产生具有含瓣膜蛋白(VCP)基因的临床突变的新型转基因小鼠,该基因负责IBM/Paget疾病/额颞痴呆。 VCP上的突变可能与IBM和某些神经退行性疾病中发现的疾病相关蛋白的异常积累有关。因此,小鼠模型将用于治疗评估和研究这些不同疾病发病机理的基础的任何共同的分子机制。后一个点值得强调,因为许多与痴呆相关的蛋白在IBM中受损受损的肌肉纤维中积累,这表明可能对这些蛋白质有协调的细胞反应。因此,从这些模型中学到的信息可能适用于痴呆症等阿尔茨海默氏病。此外,提供多种疾病模型可能会加速该领域的研究进展。通过此应用,我们希望能够提高对IBM和痴呆症的理解,并评估IBM的潜在治疗策略。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Masashi Kitazawa其他文献

Masashi Kitazawa的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Masashi Kitazawa', 18)}}的其他基金

Microglia dysregulation and SYK signaling in Alzheimer's disease
阿尔茨海默病中的小胶质细胞失调和 SYK 信号传导
  • 批准号:
    10659670
  • 财政年份:
    2023
  • 资助金额:
    $ 8.36万
  • 项目类别:
Neurotoxicity of particulate matter and its interaction with APOE in neurodegeneration
颗粒物的神经毒性及其与 APOE 在神经变性中的相互作用
  • 批准号:
    10590465
  • 财政年份:
    2022
  • 资助金额:
    $ 8.36万
  • 项目类别:
Mechanisms of particulate matter-induced neurotoxicity and cognitive decline in mice
颗粒物引起小鼠神经毒性和认知能力下降的机制
  • 批准号:
    9789887
  • 财政年份:
    2018
  • 资助金额:
    $ 8.36万
  • 项目类别:
Environmental copper exposure and its impact on microglial Abeta clearance
环境铜暴露及其对小胶质细胞 Abeta 清除的影响
  • 批准号:
    8757425
  • 财政年份:
    2014
  • 资助金额:
    $ 8.36万
  • 项目类别:
Environmental copper exposure and its impact on microglial Abeta clearance
环境铜暴露及其对小胶质细胞 Abeta 清除的影响
  • 批准号:
    8930156
  • 财政年份:
    2014
  • 资助金额:
    $ 8.36万
  • 项目类别:
Pathogenic role of valosin-containing protein (VCP) in IBMPFD
含缬洛辛蛋白 (VCP) 在 IBMPFD 中的致病作用
  • 批准号:
    8456187
  • 财政年份:
    2012
  • 资助金额:
    $ 8.36万
  • 项目类别:
Pathogenic role of valosin-containing protein (VCP) in IBMPFD
含缬洛辛蛋白 (VCP) 在 IBMPFD 中的致病作用
  • 批准号:
    8660646
  • 财政年份:
    2012
  • 资助金额:
    $ 8.36万
  • 项目类别:
Pathogenic role of valosin-containing protein (VCP) in IBMPFD
含缬洛辛蛋白 (VCP) 在 IBMPFD 中的致病作用
  • 批准号:
    8399137
  • 财政年份:
    2012
  • 资助金额:
    $ 8.36万
  • 项目类别:
Pathogenic Role of Abeta, tau and Inflammation in Inclusion Body Myositis
Abeta、tau 和炎症在包涵体肌炎中的致病作用
  • 批准号:
    7319368
  • 财政年份:
    2007
  • 资助金额:
    $ 8.36万
  • 项目类别:

相似海外基金

Supramolecular biomaterials for tuning the inflammatory properties of the complement system
用于调节补体系统炎症特性的超分子生物材料
  • 批准号:
    10538835
  • 财政年份:
    2022
  • 资助金额:
    $ 8.36万
  • 项目类别:
Supramolecular biomaterials for tuning the inflammatory properties of the complement system
用于调节补体系统炎症特性的超分子生物材料
  • 批准号:
    10631187
  • 财政年份:
    2022
  • 资助金额:
    $ 8.36万
  • 项目类别:
Temporal Biomarker-Powered Immunotherapy Targeting GFAP for Traumatic Brain Injury
靶向 GFAP 的时间生物标志物驱动的免疫疗法治疗创伤性脑损伤
  • 批准号:
    10253356
  • 财政年份:
    2021
  • 资助金额:
    $ 8.36万
  • 项目类别:
Rational Structure-Based Design of Broad Neutralizing Humanized svMP mAbs
基于合理结构的广泛中和人源化 svMP 单克隆抗体的设计
  • 批准号:
    10310508
  • 财政年份:
    2020
  • 资助金额:
    $ 8.36万
  • 项目类别:
FURTHER DEVELOPMENT OF COLOVAC, A MULTI-ANTIGEN MULTI-PEPTIDE VACCINE, FOR COLON CANCER PREVENTION
进一步开发用于预防结肠癌的多抗原多肽疫苗 COLOVAC
  • 批准号:
    10021897
  • 财政年份:
    2019
  • 资助金额:
    $ 8.36万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了